Evolus’ (EOLS) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Evolus (NASDAQ:EOLS) in a report issued on Tuesday morning, Benzinga reports. They currently have a $27.00 price objective on the stock.

EOLS has been the subject of a number of other research reports. Barclays upgraded Evolus from an equal weight rating to an overweight rating and boosted their price objective for the company from $10.00 to $16.00 in a research report on Monday, January 29th. Needham & Company LLC reissued a buy rating and set a $22.00 price target on shares of Evolus in a report on Wednesday, May 8th.

Evolus Stock Up 0.5 %

EOLS stock opened at $12.51 on Tuesday. The firm has a market cap of $783.13 million, a price-to-earnings ratio of -11.91 and a beta of 1.47. Evolus has a 1-year low of $7.07 and a 1-year high of $15.43. The firm has a fifty day moving average price of $12.93 and a two-hundred day moving average price of $11.94. The company has a debt-to-equity ratio of 6.54, a current ratio of 3.21 and a quick ratio of 2.96.

Evolus (NASDAQ:EOLS) last announced its quarterly earnings data on Thursday, March 7th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.05). The company had revenue of $61.00 million for the quarter, compared to analyst estimates of $61.14 million. Research analysts predict that Evolus will post -0.61 EPS for the current year.

Insider Buying and Selling at Evolus

In other news, CFO Sandra Beaver sold 5,672 shares of the stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $13.92, for a total value of $78,954.24. Following the completion of the transaction, the chief financial officer now directly owns 154,201 shares in the company, valued at $2,146,477.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CFO Sandra Beaver sold 5,672 shares of the firm’s stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $13.92, for a total transaction of $78,954.24. Following the completion of the transaction, the chief financial officer now owns 154,201 shares of the company’s stock, valued at $2,146,477.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider David Moatazedi sold 16,051 shares of the business’s stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $12.72, for a total transaction of $204,168.72. Following the completion of the sale, the insider now owns 673,563 shares in the company, valued at $8,567,721.36. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 61,628 shares of company stock valued at $830,947. Company insiders own 6.10% of the company’s stock.

Institutional Investors Weigh In On Evolus

Institutional investors and hedge funds have recently modified their holdings of the stock. Stonepine Capital Management LLC boosted its position in shares of Evolus by 3.0% in the 4th quarter. Stonepine Capital Management LLC now owns 5,333,004 shares of the company’s stock valued at $56,157,000 after purchasing an additional 154,000 shares during the period. Perceptive Advisors LLC lifted its stake in Evolus by 166.8% during the fourth quarter. Perceptive Advisors LLC now owns 3,963,424 shares of the company’s stock valued at $41,735,000 after buying an additional 2,477,623 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Evolus by 37.9% in the third quarter. Vanguard Group Inc. now owns 2,698,647 shares of the company’s stock worth $24,666,000 after buying an additional 741,451 shares during the period. Schroder Investment Management Group increased its position in shares of Evolus by 7.1% in the third quarter. Schroder Investment Management Group now owns 1,752,595 shares of the company’s stock worth $16,019,000 after acquiring an additional 115,647 shares in the last quarter. Finally, Lord Abbett & CO. LLC acquired a new stake in shares of Evolus during the first quarter valued at approximately $11,628,000. Institutional investors and hedge funds own 90.69% of the company’s stock.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.